Enoximone
From Wikipedia, the free encyclopedia
 |
|
|
Enoximone
|
|
| Systematic (IUPAC) name | |
| 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3- dihydroimidazol-2-one |
|
| Identifiers | |
| CAS number | 77671-31-9 |
| ATC code | C01CE03 |
| PubChem | 53708 |
| Chemical data | |
| Formula | C12H12N2O2S |
| Mol. weight | 248.302 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 50% (oral) |
| Protein binding | 85% |
| Metabolism | Hepatic oxidation |
| Half life | 4 to 10 hours |
| Excretion | Renal (60 to 70%) |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
POM(UK) |
| Routes | Intravenous |
Enoximone (INN, trade name Perfan®) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
| Selective Phosphodiesterase inhibitors (C01CE, G04BE)edit | ||
|---|---|---|
| PDE1: | ||
| PDE2: | ||
| PDE3: |
Amrinone, Bucladesine, Enoximone, Milrinone |
|
| PDE4: | ||
| PDE5: | ||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
